Our Team
Meet the team! This is our senior management and scientific team. We're involved in many different projects across the globe, dedicating the right level of experience and expertise to every client project.
Every day brings us closer to discovering a major breakthrough in the search for new drugs to prevent, alleviate or cure. Mark is passionate about translational biology and the pivotal role it has towards delivering this.
As CEO of well known CRO companies in France and Singapore, he has enjoyed a privileged position in leading and influencing vital drug discovery programmes. Here in the UK, as CEO of Transpharmation, Mark’s work continues in translational biology with innovative science at the core.
Joseph is focused on optimizing the translational value of Transpharmation's services to facilitate the development and approval of novel drugs. Joseph continues to be closely involved in projects utilizing, characterizing and developing the aged dog as a natural model of age-related human diseases.
Joseph is a strong proponent for the use of validated natural and/or translational animal models in drug discovery.
Mike Bishop joined Transpharmation in 2022 following a career that has taken him across the globe from Europe and Africa to North America. Never afraid to make a bold move, Mike is now responsible for all European revenue streams as well as HR, IT and Facilities.
Recognised for his services to leadership development at the Royal Military Academy Sandhurst by the late Queen Elizabeth II in her last Jubilee Honours, Mike is passionate about investing in and developing people to ensure they realise their maximum potential within any organisation.
As the Chief Scientific Officer of Transpharmation, Guy brings over 20 years International CNS Research and Development experience with major BioPharma organizations such as Glaxo-Wellcome, Hoffmann-La Roche, Schering Plough and NPS Pharmaceuticals.
As a leader of functional CNS groups in most of these organizations, Guy has demonstrated a sustained commitment to the development and implementation of translational animal models to support the identification and progression of novel chemical entities from early discovery through to clinical development.
Christina has been with the company since its inception in 2005 and is currently the Chief Scientific Officer for all Canine work conducted by the business.
Christina brings a breadth of operational experience having run all aspects of the research laboratory, together with a deep knowledge of Canine physiology and pharmacology.
Christina's personal scientific interests are in finding new medications to alleviate canine diseases of ageing, together with anxiety and stress. This has followed her pursuit of a PhD in the laboratory of Prof. Bill Milgram (University of Toronto), investigating the use of non-invasive imaging technologies to study brain aging.
Col is Transpharmation’s Director/Operations Lead for the UK, Project Licence Holder and Animal Welfare Advocate. With over 27 years of experience in the pharmaceutical industry at leading companies including Rhone-Poulenc and GlaxoSmithKline, Col’s knowledge is expansive across numerous therapeutic areas such as pain, diabetes, arthritis and epilepsy. As such, she is well-placed to ensure all work conducted at Transpharmation is carried out to the highest standards.
Alongside her skilled and experienced team, Col is instrumental in developing new assays and techniques for our ever-expanding portfolio of capabilities.
Jack has more than 10 years’ experience in CNS research. He is currently Head of Transpharmation’s Irish site, based at Trinity College Dublin, where he is also an Adjunct Assistant Professor in Physiology.
Jack’s experience spans psychiatric, neurodegenerative and inflammatory disorders and his research implements a translational focus ranging from preclinical models of disease to clinical biomarker discovery. Since joining Transpharmation in 2014, Jack has been instrumental in the foundation and development of the company’s R&D-focused Irish site, where he steers scientific development and manages external partnerships. Jack spent four years as the Industry Representative on the board of Ireland’s national neuroscience society, Neuroscience Ireland.
Ewa Sokolowska holds a PhD in neuroscience from the University of Zurich. She has over 15 years of experience working with different rodent models gained whilst at EMBL Monterotondo, Italy as a trainee, at the University of Zurich as a PhD student, and at the University of Helsinki during her Postdoctoral fellowship.
Ewa is also the author of several paper publications and poster abstracts. Initially, she worked at Transpharmation Ireland Ltd, where she successfully established multiple preclinical studies and leads a team of young scientists. For the last 2 years, she has lead a team of scientists at the Transpharmation Poland site. Her research interests include all aspects of novel animal models with possible high clinical significance.